515 related articles for article (PubMed ID: 28179120)
1. Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy.
Clossen BL; Reddy DS
Biochim Biophys Acta Mol Basis Dis; 2017 Jun; 1863(6):1519-1538. PubMed ID: 28179120
[TBL] [Abstract][Full Text] [Related]
2. An Insight into Molecular Mechanisms and Novel Therapeutic Approaches in Epileptogenesis.
Singh S; Singh TG; Rehni AK
CNS Neurol Disord Drug Targets; 2020; 19(10):750-779. PubMed ID: 32914725
[TBL] [Abstract][Full Text] [Related]
3. Role of hormones and neurosteroids in epileptogenesis.
Reddy DS
Front Cell Neurosci; 2013; 7():115. PubMed ID: 23914154
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic interventions for epileptogenesis: A new frontier for curing epilepsy.
Younus I; Reddy DS
Pharmacol Ther; 2017 Sep; 177():108-122. PubMed ID: 28279785
[TBL] [Abstract][Full Text] [Related]
5. Contributions of astrocytes to epileptogenesis following status epilepticus: opportunities for preventive therapy?
Gibbons MB; Smeal RM; Takahashi DK; Vargas JR; Wilcox KS
Neurochem Int; 2013 Dec; 63(7):660-9. PubMed ID: 23266599
[TBL] [Abstract][Full Text] [Related]
6. An insight into crosstalk among multiple signaling pathways contributing to epileptogenesis.
Gautam V; Rawat K; Sandhu A; Kumari P; Singh N; Saha L
Eur J Pharmacol; 2021 Nov; 910():174469. PubMed ID: 34478688
[TBL] [Abstract][Full Text] [Related]
7. Alteration of epileptogenesis genes.
Brooks-Kayal AR; Raol YH; Russek SJ
Neurotherapeutics; 2009 Apr; 6(2):312-8. PubMed ID: 19332325
[TBL] [Abstract][Full Text] [Related]
8. Disease modification in partial epilepsy.
Walker MC; White HS; Sander JW
Brain; 2002 Sep; 125(Pt 9):1937-50. PubMed ID: 12183340
[TBL] [Abstract][Full Text] [Related]
9. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy.
Löscher W
Epilepsy Res; 2002 Jun; 50(1-2):105-23. PubMed ID: 12151122
[TBL] [Abstract][Full Text] [Related]
10. The holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments.
Löscher W
Neuropharmacology; 2020 May; 167():107605. PubMed ID: 30980836
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Histone Deacetylation Inhibition Prevents the Development and Persistence of Temporal Lobe Epilepsy.
Reddy SD; Clossen BL; Reddy DS
J Pharmacol Exp Ther; 2018 Jan; 364(1):97-109. PubMed ID: 29101217
[TBL] [Abstract][Full Text] [Related]
12. Inflammation in epileptogenesis after traumatic brain injury.
Webster KM; Sun M; Crack P; O'Brien TJ; Shultz SR; Semple BD
J Neuroinflammation; 2017 Jan; 14(1):10. PubMed ID: 28086980
[TBL] [Abstract][Full Text] [Related]
13. Role of the Fyn-PKCδ signaling in SE-induced neuroinflammation and epileptogenesis in experimental models of temporal lobe epilepsy.
Sharma S; Carlson S; Puttachary S; Sarkar S; Showman L; Putra M; Kanthasamy AG; Thippeswamy T
Neurobiol Dis; 2018 Feb; 110():102-121. PubMed ID: 29197620
[TBL] [Abstract][Full Text] [Related]
14. Commonalities and differences in extracellular levels of hippocampal acetylcholine and amino acid neurotransmitters during status epilepticus and subsequent epileptogenesis in two rat models of temporal lobe epilepsy.
Meller S; Brandt C; Theilmann W; Klein J; Löscher W
Brain Res; 2019 Jun; 1712():109-123. PubMed ID: 30703372
[TBL] [Abstract][Full Text] [Related]
15. Reactive astrocyte-driven epileptogenesis is induced by microglia initially activated following status epilepticus.
Sano F; Shigetomi E; Shinozaki Y; Tsuzukiyama H; Saito K; Mikoshiba K; Horiuchi H; Cheung DL; Nabekura J; Sugita K; Aihara M; Koizumi S
JCI Insight; 2021 May; 6(9):. PubMed ID: 33830944
[TBL] [Abstract][Full Text] [Related]
16. Protective Activity of Novel Hydrophilic Synthetic Neurosteroids on Organophosphate Status Epilepticus-induced Chronic Epileptic Seizures, Non-Convulsive Discharges, High-Frequency Oscillations, and Electrographic Ictal Biomarkers.
Ramakrishnan S; Singh T; Reddy DS
J Pharmacol Exp Ther; 2024 Jan; 388(2):386-398. PubMed ID: 38050069
[TBL] [Abstract][Full Text] [Related]
17. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.
Wong M
Epilepsia; 2010 Jan; 51(1):27-36. PubMed ID: 19817806
[TBL] [Abstract][Full Text] [Related]
18. Glial source of nitric oxide in epileptogenesis: A target for disease modification in epilepsy.
Sharma S; Puttachary S; Thippeswamy T
J Neurosci Res; 2019 Nov; 97(11):1363-1377. PubMed ID: 29230865
[TBL] [Abstract][Full Text] [Related]
19. Commonalities in epileptogenic processes from different acute brain insults: Do they translate?
Klein P; Dingledine R; Aronica E; Bernard C; Blümcke I; Boison D; Brodie MJ; Brooks-Kayal AR; Engel J; Forcelli PA; Hirsch LJ; Kaminski RM; Klitgaard H; Kobow K; Lowenstein DH; Pearl PL; Pitkänen A; Puhakka N; Rogawski MA; Schmidt D; Sillanpää M; Sloviter RS; Steinhäuser C; Vezzani A; Walker MC; Löscher W
Epilepsia; 2018 Jan; 59(1):37-66. PubMed ID: 29247482
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for epileptogenesis and its treatment.
Engel J; Pitkänen A
Neuropharmacology; 2020 May; 167():107735. PubMed ID: 31377200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
